Recombinant human kallikrein-1
Highest phase reached
Phase 2
Drug type
Protein
- Listing at source
- Listed
- Highest phase reached
- Phase 2
- Drug type
- Protein
- Drug name
- Recombinant human kallikrein-1
- dm 199
- DM-199
- dm199
- Dm199
- DM199
- kallikrein 1 recombinant human
- Kallikrein-1, recombinant human
- recombinant human kallikrein 1
- Recombinant human kallikrein-1
- recombinant human tissue kallikrein 1
- RECOMBINANT HUMAN TISSUE KALLIKREIN-1
- CAS registry numbers
- 389069-73-2
- ChEMBL ID
- CHEMBL4297936
- FDA ingredient codes (UNII)
- M5EX3P489F
- First in class
- No
- Orphan designation
- No
- Condition
- Diabetes Mellitus
- Highest recorded phase
- 1
- Condition identifier
- EFO:0000400
- Subject identifier
- D003920
- Condition
- Kidney Diseases
- Highest recorded phase
- 2
- Condition identifier
- EFO:0003086
- Subject identifier
- D007674
- Condition identifier
- EFO_0000400
- Condition identifier
- EFO_0000401
- Condition identifier
- EFO_0000668
- Condition identifier
- EFO_0003086
- Highest recorded phase
- 2
- Condition identifier
- HP_0002140
- Highest recorded phase
- 2
- Condition identifier
- HP_0002637
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0002679
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005016
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005147
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005148
- Highest recorded phase
- 1
- Condition identifier
- MONDO_0005299
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0005300
- Highest recorded phase
- 2
- Condition identifier
- MONDO_0024575
- Condition identifier
- MONDO_1060198
- Highest recorded phase
- 2
- NCT01845064
- NCT04123613
- Prodrug
- No
- Inorganic
- No
- Natural product
- No
Related records
Trials (7)
- A Study to Evaluate the Safety and Effectiveness of DM199 in Healthy Subjects and Type 2 Diabetes Patients
- An Open Label, Phase 1b, Ascending Dose Study of DM199
- DM199 for Pregnancy Complications
- Evaluation to Assess Safety and Tolerability of DM199 in Subjects With Acute Ischemic Stroke
- Multiple Doses of DM199 in Patients With Chronic Kidney Disease (REDUX)
- Study to Assess PK, Safety and Tolerability in Patients With DM and CKD
- Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
In development for (9)
- Brain ischemia Phase 2
- Cerebral infarction Phase 2
- Chronic kidney disease Phase 2
- Diabetes mellitus Phase 1
- Diabetic kidney disease Phase 1
- Ischemic stroke Phase 2
- Kidney disorder Phase 2
- Type 1 diabetes mellitus Phase 1
- Type 2 diabetes mellitus Phase 1
Other linked conditions (2)
- Preeclampsia
- Pregnancy disorder